Valuation dashboard for Avalo Therapeutics, Inc. (AVTX) with P/E N/A, P/B 1.61, EV/EBITDA -9.25 and dividend yield 0.00%. DCF, Graham Number and Earnings Power Value models plus sector comparison against other Healthcare companies.
Avalo Therapeutics, Inc. is a precision medicine company in the clinical development phase, dedicated to identifying, advancing, and marketing specialized treatments for patients experiencing critical unmet medical needs across the fields of immunology, immuno-oncology, and rare genetic disorders. Among its key pipeline assets is AVTX-002, a fully human monoclonal antibody designed to inhibit LIGHT.
Analysis Summary
Avalo Therapeutics, Inc. reported revenue of $59000 in the most recent fiscal year, growing at a 5-year CAGR of -61.2%.
Trailing-twelve-month margins: gross margin -168.6%, operating margin -1548.4%, net margin -1700.6%.
At the current price of $16.58, AVTX has negative trailing earnings (P/E not meaningful) and an ROE of -58.03%. Market capitalisation stands at $872M.
Balance sheet quality for AVTX: current ratio of 8.1. A debt-to-equity below 1.0 typically signals conservative capital structure, while a current ratio above 1.5 indicates comfortable short-term liquidity.
Valuation Ratios
| Price / Book | 1.61 |
| EV / EBITDA | -9.25 |
| Dividend Yield | 0.00% |
Valuation Models
| DCF Fair Value | $0.99 |
| vs Current Price | -94.1% |
Peer Comparison
| Symbol | Company | Market Cap | P/E | P/B | ROE |
|---|---|---|---|---|---|
| AVTX | Avalo Therapeutics, Inc. | $872M | 1.61 | -58.0% | |
| 0QZU.L | Vertex Pharmaceuticals Incorporated | $131.8B | |||
| VRTX | Vertex Pharmaceuticals Incorporated | $130.6B | 29.76 | 6.46 | 23.3% |
| 0R2M.L | Regeneron Pharmaceuticals, Inc. | $84.0B | |||
| REGN | Regeneron Pharmaceuticals, Inc. | $79.8B | 18.79 | 2.57 | 13.8% |
| ARGX | argenx SE | $61.2B | 36.30 | 7.40 | 21.7% |
| MRNA | Moderna, Inc. | $57.8B | 1.34 | -39.2% | |
| RVMD | Revolution Medicines, Inc. | $41.7B | 15.96 | -96.4% |
Price
| Price | $16.58 |
| Market Cap | $872M |
| Exchange | NASDAQ |
| Country | US |
Profitability
| Return on Equity | -58.03% |
| Return on Invested Capital | -19.44% |
| Return on Assets | -20.44% |
| Gross Margin | -16861.02% |
| Operating Margin | -154844.07% |
| Net Margin | -170055.93% |
Related companies: AARD · BDTX · CHRS · CRBU · ENTA · EPRX · IVA
Explore sector: Healthcare · Biotechnology
More sections of AVTX: Overview · Financials · Statistics · Estimates · Technical · Ownership · News · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks